Search
tagraxofusp (Elzonris)
Indications:
- blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults & children >= 2 years of age
Contraindications:
- pregnancy, lactation
Adverse effects:
- nausea, fatigue, fever, chills
- peripheral edema)
- weight gain
- laboratory abnormalities
- lymphopenia, thrombocytopenia, anema
- decreased serum albumin & serum calcium
- hyperglycemia
- increased serum transaminases (serum ALT & serum AST)
Boxed warning:
- capillary leak syndrome
General
antineoplastic agent (chemotherapeutic agent)
References
- FDA News Release. Dec 21, 2018
FDA approves first treatment for rare blood disease.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629020.htm